BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cuker A, Cataland SR, Coppo P, de la Rubia J, Friedman KD, George JN, Knoebl PN, Kremer Hovinga JA, Lämmle B, Matsumoto M, Pavenski K, Peyvandi F, Sakai K, Sarode R, Thomas MR, Tomiyama Y, Veyradier A, Westwood JP, Scully M. Redefining outcomes in immune TTP: an international working group consensus report. Blood 2021;137:1855-61. [PMID: 33529333 DOI: 10.1182/blood.2020009150] [Cited by in Crossref: 11] [Cited by in F6Publishing: 28] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Graciaa S, Adeagbo S, Fong G, Rollins M, McElfresh P, Zerra PE, Bennett C, Josephson CD, Briones M, Fasano RM, Chonat S. Clinical features and neurological outcomes in pediatric immune-mediated thrombotic thrombocytopenic purpura: A report from a large pediatric hematology center. Pediatr Blood Cancer 2022;:e29992. [PMID: 36151977 DOI: 10.1002/pbc.29992] [Reference Citation Analysis]
2 Thompson GL, Kavanagh D. Diagnosis and treatment of thrombotic microangiopathy. Int J Lab Hematol 2022;44 Suppl 1:101-13. [PMID: 36074708 DOI: 10.1111/ijlh.13954] [Reference Citation Analysis]
3 George JN. Thrombotic Thrombocytopenic Purpura: From 1972 to 2022 and Beyond. Semin Thromb Hemost 2022. [PMID: 35793688 DOI: 10.1055/s-0042-1749589] [Reference Citation Analysis]
4 Yoshida K, Murata S, Morimoto M, Mushino T, Tanaka K, Yamashita Y, Hosoi H, Nishikawa A, Tamura S, Hatakeyama K, Matsumoto M, Sonoki T. Sudden Cardiac Death in a Patient with Thrombotic Thrombocytopenic Purpura: A Case Report. Hematology Reports 2022;14:203-9. [DOI: 10.3390/hematolrep14020027] [Reference Citation Analysis]
5 Bae SH, Kim SH, Bang SM. Recent advances in the management of immune-mediated thrombotic thrombocytopenic purpura. Blood Res 2022;57:37-43. [PMID: 35483924 DOI: 10.5045/br.2022.2022005] [Reference Citation Analysis]
6 Doyle AJ, Stubbs MJ, Lester W, Thomas W, Westwood J, Thomas M, Percy C, Prasannan N, Scully M. The use of obinutuzumab and ofatumumab in the treatment of immune thrombotic thrombocytopenic purpura. Br J Haematol. [DOI: 10.1111/bjh.18192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Graça NAG, Joly BS, Voorberg J, Vanhoorelbeke K, Béranger N, Veyradier A, Coppo P. TTP: From empiricism for an enigmatic disease to targeted molecular therapies. Br J Haematol 2022. [PMID: 35146746 DOI: 10.1111/bjh.18040] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Deucher W, Sukumar S, Cataland SR. Clinical relapse of immune‐mediated thrombotic thrombocytopenic purpura following COVID‐19 vaccination. Res Pract Thromb Haemost 2022;6. [DOI: 10.1002/rth2.12658] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
9 Subhan M, Scully M. Advances in the management of TTP. Blood Reviews 2022. [DOI: 10.1016/j.blre.2022.100945] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Thangaraju K, Katneni U, Akpan IJ, Tanaka K, Thomas T, Setua S, Reisz JA, Cendali F, Gamboni F, Nemkov T, Kahn S, Wei AZ, Valk JE, Hudson KE, Roh DJ, Moriconi C, Zimring JC, D'Alessandro A, Spitalnik SL, Francis RO, Buehler PW. The Impact of Age and BMI on the VWF/ADAMTS13 Axis and Simultaneous Thrombin and Plasmin Generation in Hospitalized COVID-19 Patients. Front Med (Lausanne) 2021;8:817305. [PMID: 35087853 DOI: 10.3389/fmed.2021.817305] [Reference Citation Analysis]
11 Westwood JP, Scully M. Management of acquired, immune thrombocytopenic purpura (iTTP): beyond the acute phase. Therapeutic Advances in Hematology 2022;13:204062072211122. [DOI: 10.1177/20406207221112217] [Reference Citation Analysis]
12 Palandri F, Di Pietro C, Ricci F, Tazzari PL, Randi V, Bartoletti D, Cavo M, Vianelli N, Auteri G. Immune thrombotic thrombocytopenic purpura: Personalized therapy using ADAMTS-13 activity and autoantibodies. Res Pract Thromb Haemost 2021;5:e12606. [PMID: 34938937 DOI: 10.1002/rth2.12606] [Reference Citation Analysis]
13 Tiscia G, Sartori MT, Giuffrida G, Ostuni A, Cascavilla N, Nicolosi D, Battista C, Santeramo TM, Melillo L, Giordano G, Cappucci F, Fischetti L, Chinni E, Tarantini G, Cerbo A, Bertomoro A, Fabris F, Grandone E. Focus on Key Issues in Immune Thrombotic Thrombocytopenic Purpura: Italian Experience of Six Centers. J Clin Med 2021;10:5702. [PMID: 34884404 DOI: 10.3390/jcm10235702] [Reference Citation Analysis]
14 Brodsky MA, Sukumar S, Selvakumar S, Yanek L, Hussain S, Mazepa MA, Braunstein EM, Moliterno AR, Kickler TS, Brodsky RA, Cataland SR, Chaturvedi S. Major adverse cardiovascular events in survivors of immune-mediated thrombotic thrombocytopenic purpura. Am J Hematol 2021;96:1587-94. [PMID: 34460124 DOI: 10.1002/ajh.26341] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Sukumar S, Gavriilaki E, Chaturvedi S. Updates on thrombotic thrombocytopenic purpura: Recent developments in pathogenesis, treatment and survivorship. Thrombosis Update 2021;5:100062. [DOI: 10.1016/j.tru.2021.100062] [Reference Citation Analysis]
16 Pavenski K, Huang SS, Patriquin CJ. Predictors of relapse and preventative strategies in immune thrombotic thrombocytopenic purpura. Expert Rev Hematol 2021;:1-14. [PMID: 34747320 DOI: 10.1080/17474086.2021.2003703] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Del Río-Garma J, Bobillo S, de la Rubia J, Pascual C, García-Candel F, García-Gala JM, Gonzalez R, Abril L, Vidan J, Gomez MJ, Peña F, Arbona C, Martín-Sanchez J, Moreno G, Romón I, Viejo A, Oliva A, Linares M, Salinas R, Pérez S, Garcia-Erce JA, Pereira A; “Registro Español de la Púrpura Trombocitopénica Trombótica (REPTT)”, and the “Grupo Español de Aféresis (GEA)”. Mortality in acquired thrombotic thrombocytopenic purpura in the pre-caplacizumab era. Ann Hematol 2021. [PMID: 34642787 DOI: 10.1007/s00277-021-04685-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Pavenski K. Relapse of Immune Thrombotic Thrombocytopenic Purpura Following Vaccination with COVID19 mRNA Vaccine. TH Open 2021;5:e335-7. [PMID: 34568744 DOI: 10.1055/s-0041-1732342] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
19 Aydın T, Elverdi T, Özer Çerme MD, Eşkazan AE. Intracranial hemorrhage in immune thrombotic thrombocytopenic purpura treated with caplacizumab: COMMENT from Eşkazan et al. J Thromb Haemost 2021;19:2644-6. [PMID: 34558784 DOI: 10.1111/jth.15495] [Reference Citation Analysis]
20 Poullin P. [Treatment of immune-mediated thrombotic thrombocytopenic purpura: A decisive turning point]. Transfus Clin Biol 2021;28:380-5. [PMID: 34464709 DOI: 10.1016/j.tracli.2021.08.347] [Reference Citation Analysis]
21 Bavli N, Lee N, Sarode R, Burstein E, Rambally S. Complete ADAMTS13 remission in a patient with refractory autoimmune-mediated thrombotic thrombocytopenic purpura after infliximab. Transfus Apher Sci 2021;60:103213. [PMID: 34400095 DOI: 10.1016/j.transci.2021.103213] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Gómez-Seguí I, Pascual Izquierdo C, de la Rubia Comos J. Best practices and recommendations for drug regimens and plasma exchange for immune thrombotic thrombocytopenic purpura. Expert Rev Hematol 2021;14:707-19. [PMID: 34275393 DOI: 10.1080/17474086.2021.1956898] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
23 Logothetis CN, Patel A, Eatrides J, Jaglal M, Haider M, Visweshwar N, Laber DA. Post Approval Experience with Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura at a Single Institution. J Clin Med 2021;10:3418. [PMID: 34362201 DOI: 10.3390/jcm10153418] [Reference Citation Analysis]
24 Kayashima M, Sakai K, Harada K, Kanetake J, Kubo M, Hamada E, Hayakawa M, Hatakeyama K, Matsumoto M. Strong association between insufficient plasma exchange and fatal outcomes in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura. Int J Hematol 2021;114:415-23. [PMID: 34292506 DOI: 10.1007/s12185-021-03197-5] [Reference Citation Analysis]
25 Mingot Castellano ME, Pascual Izquierdo C, González A, Viejo Llorente A, Valcarcel Ferreiras D, Sebastián E, García Candel F, Sarmiento Palao H, Gómez Seguí I, de la Rubia J, Cid J, Martínez Nieto J, Hernández Mateo L, Goterris Viciedo R, Fidalgo T, Salinas R, Del Rio-Garma J; Grupo Español de Aféresis (GEA). Recommendations for the diagnosis and treatment of patients with thrombotic thrombocytopenic purpura. Med Clin (Barc) 2021:S0025-7753(21)00332-8. [PMID: 34266669 DOI: 10.1016/j.medcli.2021.03.040] [Reference Citation Analysis]
26 Maayan H, Kirgner I, Gutwein O, Herzog-Tzarfati K, Rahimi-Levene N, Koren-Michowitz M, Blickstein D. Acquired thrombotic thrombocytopenic purpura: A rare disease associated with BNT162b2 vaccine. J Thromb Haemost 2021;19:2314-7. [PMID: 34105247 DOI: 10.1111/jth.15420] [Cited by in F6Publishing: 20] [Reference Citation Analysis]
27 Zheng XL. The standard of care for immune thrombotic thrombocytopenic purpura today. J Thromb Haemost 2021;19:1864-71. [PMID: 34060225 DOI: 10.1111/jth.15406] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
28 Lemiale V, Valade S, Mariotte E. Unresponsive Thrombotic Thrombocytopenic Purpura (TTP): Challenges and Solutions. Ther Clin Risk Manag 2021;17:577-87. [PMID: 34113115 DOI: 10.2147/TCRM.S205632] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
29 Benjamin RJ. A conceptual framework for managing iTTP. Blood 2021;137:1845-6. [PMID: 33830187 DOI: 10.1182/blood.2021011007] [Reference Citation Analysis]